Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Loss on Contract Termination

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Loss on Contract Termination

EDITAS MEDICINE, INC. (EDIT) reported Loss on Contract Termination of $4.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.

Financial Statements › Notes

us-gaap:LossOnContractTermination · last filed 2026-08-05

  • EDITAS MEDICINE, INC. loss on contract termination for the quarter ending 2025-09-30 was $0.00.
  • EDITAS MEDICINE, INC. loss on contract termination for the quarter ending 2025-06-30 was $4.80M.
  • EDITAS MEDICINE, INC. loss on contract termination for fiscal 2025 was $4.76M.
  • EDITAS MEDICINE, INC. loss on contract termination for fiscal 2024 was $0.00.
Period endLoss on Contract Termination 3 monthLoss on Contract Termination 9 monthLoss on Contract Termination 12 month
2025-12-31$4.76M
10-K · filed 2026-03-09
2025-09-30$0.00
10-Q · filed 2025-11-10
$4.76M
10-Q · filed 2025-11-10
2025-06-30$4.80M
10-Q · filed 2026-08-05
2024-12-31$0.00
10-K · filed 2026-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30